Table 3.

Regression Analysis Investigating Factors Associated With EQ‐5D‐5L Utility Index Value.

Outcome Variable	Predictor	Coefficient (β)	95% CI	P Value
EQ‐5D‐5L UI value	Demographic
	Age at inclusion	‐0.001	(‐0.002, ‐0.001)	<0.001
	BMI	‐0.006	(‐0.008, ‐0.005)	<0.001
	Sex, female	0.034	(0.004, 0.064)	0.027
	Transplant center	0.000	(‐0.021, 0.021)	1.000
	Clinical covariatesa
	In biochemical remissionb	0.024	(0.004, 0.043)	0.020
	Has cirrhosis	0.013	(‐0.009, 0.035)	0.245
	Duration of disease	0.001	(‐0.000, 0.002)	0.202
	“Normal ALT” using lower cut‐offs ALT (ALT <30 for males, ALT <19 for females)	0.006	(‐0.016, 0.029)	0.587
	Treatmenta
	Prednisolone/budesonide	‐0.030	(‐0.051, ‐0.009)	0.006
	Low dose corticosteroid (defined as either <10 mg prednisolone/day or <6 mg budesonide/day)	‐0.027	(‐0.050, ‐0.004)	0.021
	High dose corticosteroid (≥10 mg prednisolone/day or ≥6 mg budesonide/day)	‐0.035	(‐0.067, ‐0.004)	0.028
	Corticosteroid dose (log‐transformed) (corticosteroid users only, n = 545)	‐0.006	(‐0.028, 0.016)	0.582
	Azathioprine / 6‐mercaptopurine	0.009	(‐0.011, 0.030)	0.356
	MMF/MA	‐0.007	(‐0.035, 0.020)	0.594
	Tacrolimus/cyclosporine (CNIs)	‐0.077	(‐0.124, ‐0.030)	0.002
	Patient reported comorbiditiesa
	PBC	‐0.046	(‐0.088, ‐0.004)	0.033
	PSC	‐0.090	(‐0.154, ‐0.027)	0.005
	Rheumatoid arthritis	‐0.053	(‐0.092, ‐0.014)	0.008
	Osteoporosis	‐0.023	(‐0.052, 0.007)	0.132
	Ulcerative colitis/Crohn’s	‐0.031	(‐0.076, 0.014)	0.177

^aControlling for age, sex & remission status.

^bControlling for age and sex.